Company Description
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas - immunology, oncology, neuroscience, and eye care - and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at . Follow @abbvie on , , , , and .
Advances in scientific and technological research are opening up new, promising treatments for previously difficult to treat diseases, increasing the demand on already constrained healthcare budgets. The challenging economic and political environment is leading Health Technology Assessment (HTA) agencies and payers to demand better outcomes at lower cost to overall health system.
To succeed in this environment, we (AbbVie) need to fully understand market value drivers, identify the evidence required for Pricing, Reimbursement and Access (PRA), and work with the evidence generating functions to ensure that evidence generated will support successful HTA outcome and PRA negotiations.
The Global HTA Strategy team was established to realize the full value of our assets by strategically informing drug development, evidence generation and HTA submissions, aligned with HTA/payer needs. The primary goals of the function are to ensure HTA evidence requirements are considered early in the development of Abbvie assets and a robust and aligned HTA strategy across the organization in order to ensure the successful launch of Abbvie assets.
Key responsibilities:
MNCJobz.com will not be responsible for any payment made to a third-party. All Terms of Use are applicable.